A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzheimer’s disease.
This research study, called a clinical trial, is investigating how a drug known as semaglutide (often referred to as Ozempic) might impact inflammation in people living with early-stage Alzheimer's disease. Inflammation is a natural body response, but too much or the wrong kind can be harmful, especially in the brain. We're looking at whether Ozempic can change certain signs of inflammation found in blood and spinal fluid cells. Participants will receive either Ozempic or a placebo (a dummy drug with no active ingredients) to see the drug's true effects. This is a crucial 'Phase III' study, meaning it's a key step in understanding if this treatment could eventually help people with Alzheimer's.
At a glance
What is this study about?
This study is designed to explore a potential new way to help people who have early forms of Alzheimer's disease. We know that Alzheimer's can lead to memory problems and changes in thinking, and scientists are trying to understand all the factors involved. One area of interest is ‘inflammation’ – this is your body's natural response to illness or injury. Sometimes, inflammation can go wrong or become too much, and this might play a role in how Alzheimer's disease develops or gets worse.
The drug we're looking at is called semaglutide, which is already used for other health conditions. In this study, we want to see if semaglutide can affect inflammation in the brain and body of people with mild memory problems (mild cognitive impairment) or early-stage Alzheimer's dementia. We will do this by looking closely at tiny genetic messages within cells from their blood and spinal fluid to see if they change after taking the drug.
This is a comparison study, meaning some people will receive the actual drug (semaglutide at different doses), and others will receive a 'placebo' – which looks exactly like the drug but has no active ingredients. This helps us to truly understand if any changes we see are due to the semaglutide itself and not just other factors. This type of study is an important step in developing new treatments.
Key takeaways
- This study investigates if Ozempic (semaglutide) can reduce inflammation in people with early Alzheimer's.
- Participants will receive weekly injections of Ozempic or a placebo.
- Researchers will check changes in inflammation markers in blood and spinal fluid.
- The study lasts about 64 weeks, with regular clinic visits.
- It's a crucial 'Phase III' trial to understand potential new treatments.
Who may be eligible?
To join this study, we are looking for adults aged 18 or older. Both men and women are welcome to take part.
Participants must have a diagnosis of either mild cognitive impairment (MCI) or mild dementia that doctors believe is due to Alzheimer's disease. This means you might be experiencing some memory or thinking difficulties, but they are not yet severe.
The research team will carry out several checks to make sure the study is right for you, and that you meet all the health requirements to take part safely. It's important that your doctor agrees this study is suitable for your current health situation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of mild cognitive impairment or mild Alzheimer's dementia?
- Are you able to attend regular clinic appointments?
- Are you comfortable with blood tests and a lumbar puncture (spinal tap)?
What does participation involve?
If you decide to take part, you'll be assigned by chance to one of four groups – three groups will receive different doses of semaglutide (Ozempic), and one group will receive a placebo (dummy drug). Neither you nor your doctor will know which group you are in. The medication will be given as an injection under the skin, once a week, using a pre-filled pen. You'll continue with the treatment for about 64 weeks.
Throughout the study, you'll have several visits to the clinic. At certain points, blood samples will be taken, and you'll also have a procedure called a lumbar puncture (spinal tap) to collect a small amount of fluid from around your spine. These samples help us measure how the drug affects inflammation at different times, specifically at week 12. We'll also be carefully monitoring any side effects you might experience from baseline (the start) all the way through to the end of your treatment, and checking the levels of the drug in your body.
Potential risks and benefits
Locations (2)
- —UnverifiedDenmark
- —UnverifiedSweden
Common questions
What is 'inflammation' and why is it important in Alzheimer's?
Inflammation is your body's way of protecting itself, but too much or the wrong kind can be harmful, and scientists believe it might play a role in Alzheimer's disease.
What is Ozempic?
Ozempic is a brand name for the drug semaglutide, which is already used to treat conditions like type 2 diabetes. This study is exploring if it could also help with Alzheimer's.
What is a 'placebo'?
A placebo is a dummy treatment that looks just like the real medicine but contains no active drug. It helps researchers see if the real drug works better than nothing.
Will I know if I'm getting the real drug or the placebo?
No, this is a 'double-blind' study, meaning neither you nor your doctors will know whether you are receiving the active drug or the placebo until the study is over.
What is a lumbar puncture?
A lumbar puncture is a medical procedure to collect a small sample of fluid from around your spinal cord, which can give doctors clues about what's happening in your brain.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.